

RAN-Formular (Rapid-Alert-Notification) zur Mitteilung über den RAS-Verteiler

DRINGEND - BITTE SOFORT AUSLIEFERN! IMPORTANT - DELIVER IMMEDIATELY


Rapid Alert Notification of a Medicinal Product Falsification

☐ **ASSUMED**

 ☒ **REASONABLY SUSPECTED**

 ☐ **VERIFIED**

<Letter Head of Sender/Meldende Behörde>

1. To/Empfänger:		FAX
☒ Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)		0228-207-4636
☐ Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL)		030-18444-30409
☐ Paul-Ehrlich-Institut/Bundesamt für Sera und Impfstoffe (PEI)		06103-77-1263
☒ <Oberste Landesbehörde>		
2. Classification (not mandatory)	3. Falsification	
4. Product: Neupro 4mg/24h	5. Marketing Authorisation Number: EU/1/05/331/005 For use in humans	
6. Brand/Trade Name:	7. INN or Generic Name:	
8. Dosage Form: transdermal patch	9. Strength: 4mg/24h	
10. Batch number (and bulk, if different): 58033101	11. Expiry Date: 03/2022	
12. Pack size and Presentation: 28 patches, Italian presentation	13. Date Manufactured:*	
14. Marketing Authorisation Holder: UCB Pharma, B-1070 Bruxelles		
15. Manufacturer†: UCB Pharma S.A. B-1070 Bruxelles Contact Person: n.a. Telephone: n.a.	16. Recalling Firm 	
17. Rapid Alert Notification Reference Number: DE_BW_01_RAS 290_2020		
18. Details: During control of incoming goods parallel distributor ACA Mueller ADAG Pharma AG in 78244, Gottmadingen, Germany, noticed differences between purchased packages: UV sensitive fibers and the watermark are missing on the Bollini labels. The colour of the labels is white instead of cream-coloured. The number on the label is different to the number on the label pad. No recall by ACA is required as none of the packages were marketed. Suspected falsified goods are kept in separated area for rejected products.		
19. Information on distribution including exports (e. g. type of customer, e.g. hospitals): no distribution by the parallel distributor in Germany.		
20. Action taken by Issuing Authority: RA-Notification		



Baden-Württemberg
REGIERUNGSPRÄSIDIUM TÜBINGEN
LEITSTELLE ARZNEIMITTELÜBERWACHUNG

21. Proposed Action: This is the first purchase of this batch by ACA. Therefore no falsified packages were marketed by ACA. UCB Pharma (40789, Monheim, Germany) was contacted by ACA whether they could check if it is a counterfeit.		
22. From (Issuing Authority): Regierungspräsidium Tübingen Leitstelle Arzneimittelüberwachung	23. Contact Person:	
24. Signed:	25. Date: 18.08.2020	26. Time: *

* Information *not* required, when notified from outside EU.

† The holder of an authorisation referred to under Article 40 of Directive 2001/83/EC or Article 44 of Directive 2001/82/EC and the holder of the authorisation on behalf of whom the Qualified Person has certified the batch for release in accordance with Article 51 of Directive 2001/83/EC or Article 55 of Directive 2001/82/EC if different.

This is intended only for the use of the party to whom it is addressed and may contain information that is privileged, confidential, and protected from disclosure under applicable law. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please notify us by telephone immediately and return it to us at the above address by mail. Thank you.

Neupro[®] 4 mg/24 h

cerotto transdermico rotigotina

Ciascun cerotto rilascia 4 mg di rotigotina in 24 ore. Ciascun cerotto di 20 cm² contiene 9,0 mg di rotigotina.

Altri ingredienti: Poli(dimetilsilossano, trimetilsilil silicato)-copolimerizzato, povidone K90, E171, E223, E304, E307, fluoropolimero, poliestere, silicone, alluminio, pigmenti (giallo95, rosso166, rosso144, nero7). Contiene E223. Vedere il foglio illustrativo per ulteriori informazioni.

Uso transdermico. Leggere il foglio illustrativo prima dell'uso.

Tenere fuori dalla vista e dalla portata dei bambini.

Medicinale soggetto a prescrizione medica.

Non conservare a temperatura superiore ai 30°C.

ITALIA

Rappresentante locale: UCB Pharma S.p.A.
Tel: +39 / 02 300 791



Può alterare la capacità di guidare veicoli e di usare macchinari.
Da vendersi dietro presentazione di ricetta medica.
A.I.C.: 037152055/E

Prezzo: € 105,64



UCB Pharma S.A.
Allée de la Recherche 60
B-1070 Bruxelles
Belgio

EU/1/05/331/005

CIB72148A 6513255 7692

3

Neupro[®] 4 mg/24 h

cerotto transdermico rotigotina

Ciascun cerotto rilascia 4 mg di rotigotina in 24 ore. Ciascun cerotto di 20 cm² contiene 9,0 mg di rotigotina.

Altri ingredienti: Poli(dimetilsilossano, trimetilsilil silicato)-copolimerizzato, povidone K90, E171, E223, E304, E307, fluoropolimero, poliestere, silicone, alluminio, pigmenti (giallo95, rosso166, rosso144, nero7). Contiene E223. Vedere il foglio illustrativo per ulteriori informazioni.

Uso transdermico. Leggere il foglio illustrativo prima dell'uso.

Tenere fuori dalla vista e dalla portata dei bambini.

Medicinale soggetto a prescrizione medica.

Non conservare a temperatura superiore ai 30°C.

ITALIA

Rappresentante locale: UCB Pharma S.p.A.
Tel: +39 / 02 300 791



Può alterare la capacità di guidare veicoli e di usare macchinari.



UCB Pharma S.A.
Allée de la Recherche 60
B-1070 Bruxelles
Belgio

*Falsche Unterschriften
Nummern*

CIB72148A 6513255 7692

4